Quick Answer
IGC Pharma, Inc. reported Net Income Loss of -$7.12 million for the year ending 2025.
- IGC Pharma, Inc. showed an increase of +45.2% in Net Income Loss from 2024 to 2025.
- This data is from IGC Pharma, Inc.'s annual report (Form 10-K), filed with the SEC on June 27, 2025.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: -$591.2 thousand | Q4 2010: -$1.75 million | Q2 2011: -$869.2 thousand | Q3 2011: -$789.3 thousand | Q4 2011: -$1.90 million | Q2 2012: -$528.3 thousand | Q3 2012: -$142.7 thousand | Q4 2012: $310.9 thousand | Q2 2013: -$633.5 thousand | Q3 2013: -$615.2 thousand | Q4 2013: -$310.5 thousand | Q2 2014: -$1.20 million | Q3 2014: -$887.4 thousand | Q4 2014: -$590.1 thousand | Q2 2015: -$382.7 thousand | Q3 2015: -$623.4 thousand | Q4 2015: -$403.0 thousand | Q2 2016: -$383.6 thousand | Q3 2016: -$583.9 thousand | Q4 2016: -$111.6 thousand | Q2 2017: -$432.1 thousand | Q3 2017: -$304.0 thousand | Q4 2017: -$532.6 thousand | Q2 2018: -$512.0 thousand | Q3 2018: -$859.0 thousand | Q4 2018: -$1.15 million | Q2 2019: -$1.38 million | Q3 2019: -$1.18 million | Q4 2019: -$1.60 million | Q2 2020: -$1.88 million | Q3 2020: -$1.66 million | Q4 2020: -$2.32 million | Q2 2021: -$1.79 million | Q3 2021: -$4.34 million | Q4 2021: -$2.38 million | Q2 2022: -$2.79 million | Q3 2022: -$2.44 million | Q4 2022: -$2.25 million | Q2 2023: -$2.08 million | Q3 2023: -$2.45 million | Q4 2023: -$5.59 million | Q2 2024: -$2.38 million | Q3 2024: -$1.72 million | Q4 2024: -$1.83 million | Q2 2025: -$1.60 million | Q3 2025: -$1.82 million.
- Over the full 15 years of available data (2011 to 2025), IGC Pharma, Inc.'s Net Income Loss has grown by 64.8%.
- Historical annual values: Fiscal year 2025: -$7.12 million | Fiscal year 2024: -$13.00 million | Fiscal year 2023: -$11.51 million | Fiscal year 2022: -$15.02 million | Fiscal year 2021: -$8.81 million | Fiscal year 2020: -$7.32 million | Fiscal year 2019: -$4.10 million | Fiscal year 2018: -$1.79 million | Fiscal year 2017: -$1.87 million | Fiscal year 2016: -$2.81 million | Fiscal year 2015: -$4.61 million | Fiscal year 2014: -$3.02 million | Fiscal year 2013: -$2.25 million | Fiscal year 2012: -$7.75 million | Fiscal year 2011: -$20.24 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: